Luis J V Galietta

List of Publications by Year
in descending order

155	10,187	44042	37183
papers	citations	48 h-index	96 g-index

157	157	157	7552
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs. International Journal of Molecular Sciences, 2022, 23, 3175.	1.8	19
2	TMEM16A (ANO1) as a therapeutic target in cystic fibrosis. Current Opinion in Pharmacology, 2022, 64, 102206.	1.7	17
3	Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: an unprecedented property of antimicrobial peptides. Cellular and Molecular Life Sciences, 2022, 79, 1.	2.4	4
4	KCa3.1 differentially regulates trachea and bronchi epithelial gene expression in a chronic-asthma mouse model. Physiological Genomics, 2022, 54, 273-282.	1.0	1
5	Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Molecular Genetics & Genomic Medicine, 2021, 9, e1656.	0.6	21
6	Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment. International Journal of Molecular Sciences, 2021, 22, 5262.	1.8	45
7	Chloride transport modulators as drug candidates. American Journal of Physiology - Cell Physiology, 2021, 321, C932-C946.	2.1	15
8	Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene. International Journal of Molecular Sciences, 2021, 22, 11972.	1.8	21
9	Current development of CFTR potentiators in the last decade. European Journal of Medicinal Chemistry, 2020, 204, 112631.	2.6	18
10	Identification, Structureâ€“Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as a Novel Class of CFTR Potentiators. Journal of Medicinal Chemistry, 2020, 63, 11169-11194.	2.9	12
11	Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells. Cells, 2020, 9, 2090.	1.8	44
12	Pharmacoproteomics pinpoints HSP70 interaction for correction of the most frequent Wilson disease-causing mutant of ATP7B. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32453-32463.	3.3	9
13	Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel. Science Advances, 2020, 6, eaay9669.	4.7	34
14	Lack of Kcnn4 improves mucociliary clearance in muco-obstructive lung disease. JCI Insight, 2020, 5, .	2.3	11
15	Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity. Scientific Reports, 2019, 9, 10310.	1.6	8
16	An overview on chemical structures as Î”F508-CFTR correctors. European Journal of Medicinal Chemistry, 2019, 180, 430-448.	2.6	20
17	TRPV4 and purinergic receptor signalling pathways are separately linked in airway epithelia to CFTR and TMEM16A chloride channels. Journal of Physiology, 2019, 597, 5859-5878.	1.3	40
18	ANO4 (Anoctamin 4) Is a Novel Marker of Zona Glomerulosa That Regulates Stimulated Aldosterone Secretion. Hypertension, 2019, 74, 1152-1159.	1.3	15

#	Article	IF	Citations
19	High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs. Stem Cell Reports, 2019, 12, 1389-1403.	2.3	43
20	Two CFTR mutations within codon 970 differently impact on the chloride channel functionality. Human Mutation, 2019, 40, 742-748.	1.1	33
21	Peripheral localization of the epithelial sodium channel in the apical membrane of bronchial epithelial cells. Experimental Physiology, 2019, 104, 866-875.	0.9	11
22	Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools. European Journal of Medicinal Chemistry, 2018, 144, 179-200.	2.6	29
23	High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel. Journal of Biological Chemistry, 2018, 293, 1203-1217.	1.6	29
24	The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR Through an Autophagy-Independent and USP13-Mediated Mechanism. Frontiers in Pharmacology, 2018, 9, 1464.	1.6	15
25	Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance. Molecules, 2018, 23, 120.	1.7	14
26	Increased expression of ATP12A proton pump in cystic fibrosis airways. JCI Insight, 2018, 3, .	2.3	43
27	Thymosin Î±-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia. JCI Insight, 2018, 3, .	2.3	23
28	Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A). Journal of Medicinal Chemistry, 2017, 60, 4626-4635.	2.9	31
29	Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport. Current Opinion in Pharmacology, 2017, 34, 91-97.	1.7	58
30	Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation. Translational Research, 2017, 182, 14-26.e4.	2.2	15
31	CFTR pharmacology. Cellular and Molecular Life Sciences, 2017, 74, 117-128.	2.4	28
32	Intermolecular Interactions in the TMEM16A Dimer Controlling Channel Activity. Scientific Reports, 2016, 6, 38788.	1.6	11
33	Pharmacological analysis of epithelial chloride secretion mechanisms in adult murine airways. European Journal of Pharmacology, 2016, 781, 100-108.	1.7	24
34	Esculentin-1a-Derived Peptides Promote Clearance of Pseudomonas aeruginosa Internalized in Bronchial Cells of Cystic Fibrosis Patients and Lung Cell Migration: Biochemical Properties and a Plausible Mode of Action. Antimicrobial Agents and Chemotherapy, 2016, 60, 7252-7262.	1.4	47
35	Goblet Cell Hyperplasia Requires High Bicarbonate Transport To Support Mucin Release. Scientific Reports, 2016, 6, 36016.	1.6	75
36	TMEM16 Proteins: Membrane Channels with Unusual Pores. Biophysical Journal, 2016, 111, 1821-1822.	0.2	1

#	Article	IF	Citations
37	High throughput screening for modulators of ACVR1 transcription potentially applicable to the treatment of Fibrodysplasia Ossificans Progressiva. DMM Disease Models and Mechanisms, 2016, 9, 685-96.	1.2	40
38	Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator. Archiv Der Pharmazie, 2016, 349, 112-123.	2.1	11
39	Pharmacological rescue of mutant CFTR protein improves the viscoelastic properties of CF mucus. Journal of Cystic Fibrosis, 2016, 15, 295-301.	0.3	19
40	Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel. Journal of Cystic Fibrosis, 2016, 15, 425-435.	0.3	14
41	TMEM16 Proteins (Anoctamins) in Epithelia. , 2016, , 553-567.		0
42	Finding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25â€“28 March 2015. Journal of Cystic Fibrosis, 2015, 14, 700-705.	0.3	2
43	Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation. Scientific Reports, 2015, 5, 12138.	1.6	44
44	Ion channel and lipid scramblase activity associated with expression of TMEM16F/ANO6 isoforms. Journal of Physiology, 2015, 593, 3829-3848.	1.3	79
45	Development of the Olfactory Epithelium and Nasal Glands in TMEM16A-/- and TMEM16A+/+ Mice. PLoS ONE, 2015, 10, e0129171.	1.1	10
46	Upregulation of TMEM16A Protein in Bronchial Epithelial Cells by Bacterial Pyocyanin. PLoS ONE, 2015, 10, e0131775.	1.1	31
47	Synthesis and structureâ€“activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis. European Journal of Medicinal Chemistry, 2015, 99, 14-35.	2.6	31
48	Novel Hits in the Correction of Î”F508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-d]pyrimidines for the Potential Treatment of Cystic Fibrosis. Journal of Medicinal Chemistry, 2015, 58, 9697-9711.	2.9	14
49	Targeting ion channels in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 561-570.	0.3	126
50	Functional analysis of acid-activated Clâ¯ channels: Properties and mechanisms of regulation. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 105-114.	1.4	35
51	Identification and characterization of a novel promoter for the human ANO1 gene regulated by the transcription factor signal transducer and activator of transcription 6 (STAT6). FASEB Journal, 2015, 29, 152-163.	0.2	37
52	Unravelling druggable signalling networks that control F508del-CFTR proteostasis. ELife, 2015, 4, .	2.8	22
53	The search for a common structural moiety among selected pharmacological correctors of the mutant CFTR chloride channel. Future Medicinal Chemistry, 2014, 6, 1857-1868.	1.1	3
54	Structure and Function of TMEM16 Proteins (Anoctamins). Physiological Reviews, 2014, 94, 419-459.	13.1	414

#	Article	IF	Citations
55	Non-canonical translation start sites in the TMEM16A chloride channel. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 89-97.	1.4	24
56	The TMEM16A chloride channel as an alternative therapeutic target in cystic fibrosis. International Journal of Biochemistry and Cell Biology, 2014, 52, 73-76.	1.2	63
57	Correcting the basic ion transport defects in cystic fibrosis. , 2014, , 116-128.		1
58	TMEM16A alternative splicing coordination in breast cancer. Molecular Cancer, 2013, 12, 75.	7.9	37
59	New Pulmonary Therapies Directed at Targets Other than CFTR. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a009787-a009787.	2.9	15
60	Alternative Splicing of In-Frame Exon Associated with Premature Termination Codons: Implications for Readthrough Therapies. Human Mutation, 2013, 34, 287-291.	1.1	11
61	A novel missense mutation in ANO5/TMEM16E is causative for gnathodiaphyseal dyplasia in a large Italian pedigree. European Journal of Human Genetics, 2013, 21, 613-619.	1.4	53
62	Epithelial Sodium Channel Silencing as a Strategy to Correct the Airway Surface Fluid Deficit in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 445-452.	1.4	27
63	TMEM16Aâ€“TMEM16B chimaeras to investigate the structureâ€“function relationship of calcium-activated chloride channels. Biochemical Journal, 2013, 452, 443-455.	1.7	35
64	Managing the Underlying Cause of Cystic Fibrosis: A Future Role for Potentiators and Correctors. Paediatric Drugs, 2013, 15, 393-402.	1.3	38
65	DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal Tumors. Cancer Research, 2013, 73, 3661-3670.	0.4	68
66	Ligand-based design, in silico ADME-Tox filtering, synthesis and biological evaluation to discover new soluble 1,4-DHP-based CFTR activators. European Journal of Medicinal Chemistry, 2012, 55, 188-194.	2.6	6
67	Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia. Molecular Biology of the Cell, 2012, 23, 4188-4202.	0.9	96
68	Asymmetric 4â€Arylâ€1,4â€dihydropyridines Potentiate Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). ChemMedChem, 2012, 7, 1799-1807.	1.6	3
69	The anoctamin family: TMEM16A and TMEM16B as calciumâ€activated chloride channels. Experimental Physiology, 2012, 97, 177-183.	0.9	50
70	Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia. Journal of Physiology, 2012, 590, 6141-6155.	1.3	151
71	Pharmacological Correctors of Mutant CFTR Mistrafficking. Frontiers in Pharmacology, 2012, 3, 175.	1.6	22
72	Ca²⁺â€Activated Cl^{â^'}Channels. , 2011, 1, 2155-2174.		20

#	Article	IF	Citations
73	A minimal isoform of the TMEM16A protein associated with chloride channel activity. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2214-2223.	1.4	32
74	Cystic Fibrosis: A New Target for 4-Imidazo[2,1-b]thiazole-1,4-dihydropyridines. Journal of Medicinal Chemistry, 2011, 54, 3885-3894.	2.9	45
75	Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. American Journal of Physiology - Cell Physiology, 2011, 301, C872-C885.	2.1	79
76	Dual Activity of Aminoarylthiazoles on the Trafficking and Gating Defects of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Caused by Cystic Fibrosis Mutations. Journal of Biological Chemistry, 2011, 286, 15215-15226.	1.6	55
77	Altered Expression of Ano1 Variants in Human Diabetic Gastroparesis. Journal of Biological Chemistry, 2011, 286, 13393-13403.	1.6	95
78	High-Throughput Screening of Libraries of Compounds to Identify CFTR Modulators. Methods in Molecular Biology, 2011, 741, 13-21.	0.4	29
79	TMEM16A Protein: A New Identity for Ca²⁺-Dependent Cl^{â^'} Channels. Physiology, 2010, 25, 357-363.	1.6	97
80	Modulation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity and Genistein Binding by Cytosolic pH*. Journal of Biological Chemistry, 2010, 285, 41591-41596.	1.6	13
81	Alternative Splicing at a NAGNAG Acceptor Site as a Novel Phenotype Modifier. PLoS Genetics, 2010, 6, e1001153.	1.5	49
82	Influence of cell background on pharmacological rescue of mutant CFTR. American Journal of Physiology - Cell Physiology, 2010, 298, C866-C874.	2.1	118
83	IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions. PLoS ONE, 2009, 4, e6119.	1.1	43
84	Mutation-Specific Potency and Efficacy of Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Potentiators. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 783-791.	1.3	32
85	Epithelial Sodium Channel Inhibition in Primary Human Bronchial Epithelia by Transfected siRNA. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 211-216.	1.4	34
86	Regulation of TMEM16A Chloride Channel Properties by Alternative Splicing. Journal of Biological Chemistry, 2009, 284, 33360-33368.	1.6	188
87	The Combined Therapeutic Effects of Bortezomib and Fenretinide on Neuroblastoma Cells Involve Endoplasmic Reticulum Stress Response. Clinical Cancer Research, 2009, 15, 1199-1209.	3.2	39
88	Chloride channels as drug targets. Nature Reviews Drug Discovery, 2009, 8, 153-171.	21.5	400
89	Synthesis of 4-thiophen-2â€²-yl-1,4-dihydropyridines as potentiators of the CFTR chloride channel. Bioorganic and Medicinal Chemistry, 2009, 17, 7894-7903.	1.4	21
90	The TMEM16 Protein Family: A New Class of Chloride Channels?. Biophysical Journal, 2009, 97, 3047-3053.	0.2	114

#	Article	IF	Citations
91	New Genetic and Pharmacological Treatments for Cystic Fibrosis. Current Pediatric Reviews, 2009, 5, 8-27.	0.4	2
92	Analysis of ion transport in the airway epithelium using RNA interference. Current Opinion in Molecular Therapeutics, 2009, 11, 282-91.	2.8	2
93	Nanomolar CFTR Inhibition by Pore-Occluding Divalent Polyethylene Glycol-Malonic Acid Hydrazides. Chemistry and Biology, 2008, 15, 718-728.	6.2	33
94	TMEM16A, A Membrane Protein Associated with Calcium-Dependent Chloride Channel Activity. Science, 2008, 322, 590-594.	6.0	1,124
95	Î±-Aminoazaheterocyclic-Methylglyoxal Adducts Do Not Inhibit Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Activity. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 529-535.	1.3	4
96	Evidence for direct CFTR inhibition by CFTRinh-172 based on Arg347 mutagenesis. Biochemical Journal, 2008, 413, 135-142.	1.7	96
97	Proteomic analysis of the airway surface liquid: modulation by proinflammatory cytokines. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L185-L198.	1.3	51
98	Cell-based imaging of sodium iodide symporter activity with the yellow fluorescent protein variant YFP-H148Q/I152L. American Journal of Physiology - Cell Physiology, 2007, 292, C814-C823.	2.1	25
99	Thiocyanate Transport in Resting and IL-4-Stimulated Human Bronchial Epithelial Cells: Role of Pendrin and Anion Channels. Journal of Immunology, 2007, 178, 5144-5153.	0.4	133
100	Structure-Activity Relationship of 1,4-Dihydropyridines as Potentiators of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel. Molecular Pharmacology, 2007, 72, 197-207.	1.0	34
101	Functional Analysis of Mutations in the Putative Binding Site for Cystic Fibrosis Transmembrane Conductance Regulator Potentiators. Journal of Biological Chemistry, 2007, 282, 9098-9104.	1.6	32
102	Lectin Conjugates as Potent, Nonabsorbable CFTR Inhibitors for Reducing Intestinal Fluid Secretion in Cholera. Gastroenterology, 2007, 132, 1234-1244.	0.6	49
103	Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins. European Journal of Pharmacology, 2007, 560, 127-131.	1.7	16
104	The Importance of Differentiating Gelsolin Isoforms. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 685a-685a.	2.5	0
105	Contribution of CFTR to apical-basolateral fluid transport in cultured human alveolar epithelial type II cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L242-L249.	1.3	142
106	CFTR Chloride Channel Drug Discovery - Inhibitors as Antidiarrheals and Activators for Therapy of Cystic Fibrosis. Current Pharmaceutical Design, 2006, 12, 2235-2247.	0.9	81
107	In Vitro/Ex Vivo Fluorescence Assays of CFTR Chloride Channel Function. , 2005, 34, 93-101.		1
108	4-Chlorobenzo[F]isoquinoline (CBIQ), a novel activator of CFTR and Î”F508 CFTR. European Journal of Pharmacology, 2005, 516, 118-124.	1.7	22

#	Article	IF	Citations
109	Antihypertensive 1,4-Dihydropyridines as Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating Defect Caused by Cystic Fibrosis Mutations. Molecular Pharmacology, 2005, 68, 1736-1746.	1.0	52
110	Gelsolin Secretion in Interleukin-4â€“treated Bronchial Epithelia and in Asthmatic Airways. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1090-1096.	2.5	47
111	Phenylglycine and Sulfonamide Correctors of Defective Î”F508 and G551D Cystic Fibrosis Transmembrane Conductance Regulator Chloride-Channel Gating. Molecular Pharmacology, 2005, 67, 1797-1807.	1.0	145
112	Small-molecule correctors of defective ÂF508-CFTR cellular processing identified by high-throughput screening. Journal of Clinical Investigation, 2005, 115, 2564-2571.	3.9	502
113	Effect of Inflammatory Stimuli on Airway Ion Transport. Proceedings of the American Thoracic Society, 2004, 1, 62-65.	3.5	24
114	Double Mechanism for Apical Tryptophan Depletion in Polarized Human Bronchial Epithelium. Journal of Immunology, 2004, 173, 542-549.	0.4	20
115	Evidence against the Rescue of Defective Î”F508-CFTR Cellular Processing by Curcumin in Cell Culture and Mouse Models. Journal of Biological Chemistry, 2004, 279, 40629-40633.	1.6	101
116	Discovery of Glycine Hydrazide Pore-occluding CFTR Inhibitors. Journal of General Physiology, 2004, 124, 125-137.	0.9	243
117	Identification of CFTR activators and inhibitors: chance or design?. Current Opinion in Pharmacology, 2004, 4, 497-503.	1.7	17
118	Altered channel gating mechanism for CFTR inhibition by a highâ€affinity thiazolidinone blocker. FEBS Letters, 2004, 558, 52-56.	1.3	103
119	Application of Green Fluorescent Protein-Based Chloride Indicators for Drug Discovery by High-Throughput Screening. , 2004, , 85-98.		0
120	3-(2-Benzyloxyphenyl)isoxazoles and Isoxazolines: Synthesis and Evaluation as CFTR Activators.. ChemInform, 2003, 34, no.	0.1	0
121	3-(2-Benzyloxyphenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2509-2512.	1.0	39
122	Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorganic and Medicinal Chemistry, 2003, 11, 4113-4120.	1.4	62
123	Nanomolar Affinity Small Molecule Correctors of Defective Î”F508-CFTR Chloride Channel Gating. Journal of Biological Chemistry, 2003, 278, 35079-35085.	1.6	192
124	CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 285, L180-L188.	1.3	55
125	IL-4 Is a Potent Modulator of Ion Transport in the Human Bronchial Epithelium In Vitro. Journal of Immunology, 2002, 168, 839-845.	0.4	124
126	High-affinity Activators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Conductance Identified by High-throughput Screening. Journal of Biological Chemistry, 2002, 277, 37235-37241.	1.6	163

#	Article	IF	Citations
127	Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. British Journal of Pharmacology, 2002, 137, 504-512.	2.7	52
128	Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxinâ€“induced intestinal fluid secretion. Journal of Clinical Investigation, 2002, 110, 1651-1658.	3.9	490
129	Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxinâ€“induced intestinal fluid secretion. Journal of Clinical Investigation, 2002, 110, 1651-1658.	3.9	375
130	Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Letters, 2001, 499, 220-224.	1.3	320
131	Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation. American Journal of Physiology - Cell Physiology, 2001, 281, C1657-C1666.	2.1	44
132	Novel CFTR Chloride Channel Activators Identified by Screening of Combinatorial Libraries Based on Flavone and Benzoquinolizinium Lead Compounds. Journal of Biological Chemistry, 2001, 276, 19723-19728.	1.6	197
133	Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. Journal of Cell Science, 2001, 114, 4073-4081.	1.2	108
134	Properties of CFTR activated by the xanthine derivative X-33 in human airway Calu-3 cells. American Journal of Physiology - Cell Physiology, 2000, 279, C1925-C1937.	2.1	31
135	Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-Î³. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L1186-L1194.	1.3	73
136	Autocrine Regulation of Volume-sensitive Anion Channels in Airway Epithelial Cells by Adenosine. Journal of Biological Chemistry, 1999, 274, 11701-11707.	1.6	41
137	Development of Substituted Benzo[c]quinolizinium Compounds as Novel Activators of the Cystic Fibrosis Chloride Channel. Journal of Biological Chemistry, 1999, 274, 27415-27425.	1.6	102
138	Characterization of a murine gene homologous to the bovine CaCC chloride channel. Gene, 1999, 228, 181-188.	1.0	47
139	KCNE1-like Gene Is Deleted in AMME Contiguous Gene Syndrome: Identification and Characterization of the Human and Mouse Homologs. Genomics, 1999, 60, 251-257.	1.3	72
140	Insensitivity of volume-sensitive chloride currents to chromones in human airway epithelial cells. British Journal of Pharmacology, 1998, 125, 1382-1386.	2.7	1
141	An improved method to obtain highly differentiated monolayers of human bronchial epithelial cells. In Vitro Cellular and Developmental Biology - Animal, 1998, 34, 478-481.	0.7	38
142	Characterization of the human gene coding for the swelling-dependent chloride channel ICln at position 11q13.5â€“14.1 (CLNS1A) and further characterization of the chromosome 6 (CLNS1B) localization. Gene, 1998, 209, 59-63.	1.0	5
143	An electrogenic amino acid transporter in the apical membrane of cultured human bronchial epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 275, L917-L923.	1.3	31
144	Chromosomal Localization of the Genes (CLNS1A and CLNS1B) Coding for the Swelling-Dependent Chloride Channel ICln. Genomics, 1996, 38, 438-441.	1.3	10

#	Article	IF	Citations
145	Molecular cloning and functional characterization of a GABA/betaine transporter from human kidney. FEBS Letters, 1995, 373, 229-233.	1.3	66
146	Regulation of transepithelial ion transport by two different purinoceptors in the apical membrane of canine kidney (MDCK) cells. British Journal of Pharmacology, 1995, 114, 1052-1056.	2.7	47
147	Activation of Ca2+-dependent K+ and Cl? currents by UTP and ATP in CFPAC-1 cells. Pflugers Archiv European Journal of Physiology, 1994, 426, 534-541.	1.3	35
148	A volume-sensitive chloride conductance revealed in cultured human keratinocytes by 36Clâ^' efflux and whole-cell patch clamp recording. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1112, 39-44.	1.4	21
149	Extracellular 2-chloroadenosine and ATP stimulate volume-sensitive Clâ^'current and calcium mobilization in human tracheal 9HTEoâ^' cells. FEBS Letters, 1992, 304, 61-65.	1.3	28
150	A forskolin and verapamil sensitive K+ current in human tracheal cells. Biochemical and Biophysical Research Communications, 1991, 179, 1155-1160.	1.0	18
151	Characterization of chloride and cation channels in cultured human keratinocytes. Pflugers Archiv European Journal of Physiology, 1991, 418, 18-25.	1.3	36
152	Why is the cystic fibrosis gene so frequent?. Human Genetics, 1989, 84, 1-5.	1.8	97
153	A class of non-selective cation channels in human fibroblasts. FEBS Letters, 1989, 253, 43-46.	1.3	7
154	Low Ca2+-sensitive maxi-K+ channels in human cultured fibroblasts. Pflugers Archiv European Journal of Physiology, 1988, 413, 99-101.	1.3	7
155	A large conductance Clâ^' channel revealed by patch-recordings in human fibroblasts. Biochemical and Biophysical Research Communications, 1988, 154, 719-726.	1.0	33